Development of novel agents for bladder cancer

Noah M. Hahn, Thomas Powles, Christopher J. Sweeney

Research output: Contribution to journalReview articlepeer-review


Traditional treatment options for bladder cancer include transurethral resection and intravesical Bacillus Calmette Guerin for early stage disease and cystectomy or radiation therapy (with or without chemotherapy) for muscle-invasive disease. Platinum-based chemotherapy improves patient outcomes in both the perioperative and metastatic setting. Despite an increase in new therapeutic options over the past decade for many cancer patients, similar advances in bladder cancer are limited. In recent years, an improved understanding of the molecular forces driving bladder cancer development and progression has unfolded. These discoveries create a set of innovative therapeutic opportunities in bladder cancer. This review examines novel anti-cancer agents currently in clinical trials with preclinical rationale to support evaluation in bladder cancer. In addition, strategies to match a patient's tumor to the most appropriate agent are discussed. This may provide a more rational approach to evaluating the role of emerging anti-cancer agents in bladder cancer.

Original languageEnglish (US)
Pages (from-to)160-169
Number of pages10
JournalUpdate on Cancer Therapeutics
Issue number4
StatePublished - May 2009
Externally publishedYes


  • Angiogenesis
  • Bladder Cancer
  • Chemotherapy
  • Clinical Trial Design
  • EGFR
  • Epigenetics
  • HER-2
  • NFκB
  • Novel Agents
  • PI3 kinase

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Development of novel agents for bladder cancer'. Together they form a unique fingerprint.

Cite this